JÃ¼rgen Floege

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/12137939/publications.pdf

Version: 2024-02-01

361 papers	28,173 citations	4146 87 h-index	6996 154 g-index
368 all docs	368 docs citations	368 times ranked	20243 citing authors

#	Article	IF	Citations
1	Joint European League Against Rheumatism and European Renal Associationâ€“European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Annals of the Rheumatic Diseases, 2012, 71, 1771-1782.	0.9	868
2	Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet, The, 2003, 361, 827-833.	13.7	822
3	Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. New England Journal of Medicine, 2012, 367, 2482-2494.	27.0	805
4	The serum protein Î±2â€“Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. Journal of Clinical Investigation, 2003, 112, 357-366.	8.2	805
5	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, S1-S276.	5.2	782
6	Cardiovascular Disease in Chronic Kidney Disease. Circulation, 2021, 143, 1157-1172.	1.6	680
7	Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nature Reviews Nephrology, 2010, 6, 643-656.	9.6	517
8	Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. New England Journal of Medicine, 2015, 373, 2225-2236.	27.0	516
9	Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nature Genetics, 2014, 46, 1187-1196.	21.4	505
10	The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrology Dialysis Transplantation, 2011, 26, 1327-1339.	0.7	491
11	Recruitment of Podocytes from Glomerular Parietal Epithelial Cells. Journal of the American Society of Nephrology: JASN, 2009, 20, 333-343.	6.1	418
12	Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrology Dialysis Transplantation, 2011, 26, 1948-1955.	0.7	412
13	Decoding myofibroblast origins in human kidney fibrosis. Nature, 2021, 589, 281-286.	27.8	380
14	Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy. JAMA - Journal of the American Medical Association, 2017, 318, 432.	7.4	376
15	Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney International, 1992, 41, 297-309.	5.2	369
16	Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney International, 2000, 57, 167-182.	5.2	333
17	Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, 753-779.	5.2	325
18	Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis. PLoS Genetics, 2012, 8, e1002765.	3.5	301

#	Article	IF	Citations
19	Cellular events in the evolution of experimental diabetic nephropathy. Kidney International, 1995, 47, 935-944.	5.2	296
20	Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet, The, 2017, 389, 2117-2127.	13.7	278
21	Transplanted Mesenchymal Stem Cells Accelerate Glomerular Healing in Experimental Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2006, 17, 2202-2212.	6.1	276
22	Nanoparticle-Based Test Measures Overall Propensity for Calcification in Serum. Journal of the American Society of Nephrology: JASN, 2012, 23, 1744-1752.	6.1	275
23	A New Look at Platelet-Derived Growth Factor in Renal Disease. Journal of the American Society of Nephrology: JASN, 2008, 19, 12-23.	6.1	272
24	VEGF165 mediates glomerular endothelial repair. Journal of Clinical Investigation, 1999, 104, 913-923.	8.2	268
25	Mesenchymal Stem Cells Prevent Progressive Experimental Renal Failure but Maldifferentiate into Glomerular Adipocytes. Journal of the American Society of Nephrology: JASN, 2007, 18, 1754-1764.	6.1	265
26	Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis. Circulation, 2015, 132, 27-39.	1.6	259
27	Effect of Vitamin K2 Supplementation on Functional Vitamin K Deficiency in Hemodialysis Patients: A Randomized Trial. American Journal of Kidney Diseases, 2012, 59, 186-195.	1.9	257
28	Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney International, 1996, 49, 666-678.	5.2	254
29	Increased synthesis of extracellular matrix in mesangial proliferative nephritis. Kidney International, 1991, 40, 477-488.	5.2	249
30	Novel Approach to Specific Growth Factor Inhibition in Vivo. American Journal of Pathology, 1999, 154, 169-179.	3.8	239
31	Identification and Functional Characterization of Dendritic Cells in the Healthy Murine Kidney and in Experimental Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2004, 15, 613-621.	6.1	218
32	Tracing the Origin of Glomerular Extracapillary Lesions from Parietal Epithelial Cells. Journal of the American Society of Nephrology: JASN, 2009, 20, 2604-2615.	6.1	218
33	Circulating Nonphosphorylated Carboxylated Matrix Gla Protein Predicts Survival in ESRD. Journal of the American Society of Nephrology: JASN, 2011, 22, 387-395.	6.1	207
34	Vascular calcification in chronic kidney disease: an update. Nephrology Dialysis Transplantation, 2016, 31, 31-39.	0.7	203
35	Primary glomerulonephritides. Lancet, The, 2016, 387, 2036-2048.	13.7	202
36	WNTâ€“Î²-catenin signalling â€” a versatile player in kidney injury and repair. Nature Reviews Nephrology, 2021, 17, 172-184.	9.6	200

#	Article	IF	Citations
37	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 268-280.	5.2	198
38	Parietal Epithelial Cells Participate in the Formation of Sclerotic Lesions in Focal Segmental Glomerulosclerosis. Journal of the American Society of Nephrology: JASN, 2011, 22, 1262-1274.	6.1	186
39	Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury. Journal of Clinical Investigation, 2009, 119, 1286-1297.	8.2	180
40	Vascular calcification in patients with end-stage renal disease. Nephrology Dialysis Transplantation, 2004, 19, v59-v66.	0.7	166
41	Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis. Journal of the American Society of Nephrology: JASN, 2015, 26, 1466-1475.	6.1	163
42	GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. Journal of the American Society of Nephrology: JASN, 2019, 30, 1735-1745.	6.1	163
43	IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2000, 11, 2395-2403.	6.1	161
44	Fetuin-A Protects against Atherosclerotic Calcification in CKD. Journal of the American Society of Nephrology: JASN, 2009, 20, 1264-1274.	6.1	160
45	Early Mechanisms of Renal Injury in Hypercholesterolemic or Hypertriglyceridemic Rats. Journal of the American Society of Nephrology: JASN, 2000, 11, 669-683.	6.1	159
46	Ultrastructural Analysis of Vascular Calcifications in Uremia. Journal of the American Society of Nephrology: JASN, 2010, 21, 689-696.	6.1	157
47	Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD. Journal of the American Society of Nephrology: JASN, 2017, 28, 1867-1876.	6.1	157
48	A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney International, 2014, 86, 638-647.	5.2	154
49	Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis. Kidney International, 1993, 43, 369-380.	5.2	149
50	SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids. Cell Stem Cell, 2022, 29, 217-231.e8.	11.1	146
51	Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE). Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 898-905.	4.5	144
52	Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrology Dialysis Transplantation, 2015, 30, 1542-1551.	0.7	140
53	Origin of regenerating tubular cells after acute kidney injury. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1533-1538.	7.1	139
54	Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney International, 2013, 84, 998-1008.	5.2	136

#	Article	IF	Citations
55	PDGF in organ fibrosis. Molecular Aspects of Medicine, 2018, 62, 44-62.	6.4	135
56	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 281-295.	5.2	135
57	Treatment targets in renal fibrosis. Nephrology Dialysis Transplantation, 2007, 22, 3391-3407.	0.7	132
58	Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort. Nephrology Dialysis Transplantation, 2015, 30, 441-451.	0.7	132
59	The Montreal Cognitive Assessment (MoCA) - A Sensitive Screening Instrument for Detecting Cognitive Impairment in Chronic Hemodialysis Patients. PLoS ONE, 2014, 9, e106700.	2.5	130
60	Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 469-481.	4.5	128
61	Associations of FGF-23 and sKlotho with Cardiovascular Outcomes among Patients with CKD Stages 2â€“4. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1049-1058.	4.5	126
62	Regardless of etiology, progressive renal disease causes ultrastructural and functional alterations of peritubular capillaries. Kidney International, 2017, 91, 70-85.	5.2	122
63	Age-related glomerulosclerosis and interstitial fibrosis in Milan normotensive rats: A podocyte disease. Kidney International, 1997, 51, 230-243.	5.2	117
64	The ERA-EDTA database on recurrent glomerulonephritis following renal transplantation. Nephrology Dialysis Transplantation, 2014, 29, 15-21.	0.7	116
65	Albumin Is Recycled from the Primary Urine by Tubular Transcytosis. Journal of the American Society of Nephrology: JASN, 2013, 24, 1966-1980.	6.1	115
66	Calcification Propensity and Survival among Renal Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2016, 27, 239-248.	6.1	115
67	Calcification and Cardiovascular Health. Hypertension, 2006, 47, 1027-1034.	2.7	114
68	Slower Progress of Aortic Valve Calcification With Vitamin K Supplementation. Circulation, 2017, 135, 2081-2083.	1.6	114
69	Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry. Nephrology Dialysis Transplantation, 2017, 32, gfv438.	0.7	113
70	Quantitative Micro-Computed Tomography Imaging of Vascular Dysfunction in Progressive Kidney Diseases. Journal of the American Society of Nephrology: JASN, 2016, 27, 520-532.	6.1	112
71	Genetic Heterogeneity in Italian Families with IgA Nephropathy: Suggestive Linkage for Two Novel IgA Nephropathy Loci. American Journal of Human Genetics, 2006, 79, 1130-1134.	6.2	111
72	High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrology Dialysis Transplantation, 2015, 30, 288-293.	0.7	111

#	Article	IF	Citations
73	Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrology Dialysis Transplantation, 2015, 30, 1037-1046.	0.7	109
74	Treatment of Renal Fibrosisâ€"Turning Challenges into Opportunities. Advances in Chronic Kidney Disease, 2017, 24, 117-129.	1.4	109
75	The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 800-807.	4.5	107
76	Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial. Journal of the American Heart Association, 2014, 3, e001363.	3.7	105
77	Demonstration of PDGF B-chain mRNA in glomeruli in mesangial proliferative nephritis by in situ hybridization. Kidney International, 1991, 40, 470-476.	5.2	103
78	PDGF-C Is a Proinflammatory Cytokine that Mediates Renal Interstitial Fibrosis. Journal of the American Society of Nephrology: JASN, 2008, 19, 281-289.	6.1	103
79	After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney International, 2020, 98, 1044-1052.	5.2	103
80	Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy. JAMA - Journal of the American Medical Association, 2022, 327, 1888.	7.4	103
81	The mucosaâ€"kidney axis in IgA nephropathy. Nature Reviews Nephrology, 2016, 12, 147-156.	9.6	101
82	Complement C5 Mediates Experimental Tubulointerstitial Fibrosis. Journal of the American Society of Nephrology: JASN, 2007, 18, 1508-1515.	6.1	100
83	Deficiencies of calcium-regulatory proteins in dialysis patients: A novel concept of cardiovascular calcification in uremia. Kidney International, 2003, 63, S84-S87.	5.2	99
84	Recurrent IgA nephropathy after renal transplantation. Seminars in Nephrology, 2004, 24, 287-291.	1.6	99
85	Sodium thiosulfate in the treatment of calcific uremic arteriolopathy. Nature Reviews Nephrology, 2009, 5, 539-543.	9.6	98
86	The Regenerative Potential of Parietal Epithelial Cells in Adult Mice. Journal of the American Society of Nephrology: JASN, 2014, 25, 693-705.	6.1	96
87	High cardiovascular event rates occur within the first weeks of starting hemodialysis. Kidney International, 2015, 88, 1117-1125.	5.2	96
88	Deep Learningâ€"Based Segmentation and Quantification in Experimental Kidney Histopathology. Journal of the American Society of Nephrology: JASN, 2021, 32, 52-68.	6.1	93
89	GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway. PLoS Genetics, 2017, 13, e1006609.	3.5	92
90	Inflammation Modifies the Paradoxical Association between Body Mass Index and Mortality in Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2016, 27, 1479-1486.	6.1	91

#	Article	IF	Citations
91	Fetuin-A (AHSG) prevents extraosseous calcification induced by uraemia and phosphate challenge in mice. Nephrology Dialysis Transplantation, 2007, 22, 1537-1546.	0.7	87
92	The renal (myo-)fibroblast: a heterogeneous group of cells. Nephrology Dialysis Transplantation, 2012, 27, 3027-3036.	0.7	87
93	The Pathogenesis of IgA Nephropathy: What Is New and How Does It Change Therapeutic Approaches?. American Journal of Kidney Diseases, 2011, 58, 992-1004.	1.9	85
94	Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy. Kidney International Reports, 2020, 5, 2032-2041.	0.8	84
95	Current Therapy for IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2011, 22, 1785-1794.	6.1	83
96	Notchâ€3 receptor activation drives inflammation and fibrosis following tubulointerstitial kidney injury. Journal of Pathology, 2012, 228, 286-299.	4.5	83
97	Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrology Dialysis Transplantation, 2006, 21, 1293-1299.	0.7	82
98	PDGF and the progression of renal disease. Nephrology Dialysis Transplantation, 2014, 29, i45-i54.	0.7	82
99	Detection of Activated Parietal Epithelial Cells on the Glomerular Tuft Distinguishes Early Focal Segmental Glomerulosclerosis from Minimal Change Disease. American Journal of Pathology, 2014, 184, 3239-3248.	3.8	81
100	Cardiac Remodeling in Chronic Kidney Disease. Toxins, 2020, 12, 161.	3.4	81
101	Chronic kidney disease growth factors in renal fibrosis. Clinical and Experimental Pharmacology and Physiology, 2011, 38, 441-450.	1.9	80
102	Treatment of IgA nephropathy and Henochâ€“SchÃ¶nlein nephritis. Nature Reviews Nephrology, 2013, 9, 320-327.	9.6	80
103	COSMOS: the dialysis scenario of CKDâ€“MBD in Europe. Nephrology Dialysis Transplantation, 2013, 28, 1922-1935.	0.7	79
104	Vascular access calcification predicts mortality in hemodialysis patients. Kidney International, 2008, 74, 1582-1587.	5.2	78
105	Impaired vitamin K recycling in uremia is rescued by vitamin K supplementation. Kidney International, 2014, 86, 286-293.	5.2	78
106	Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrology Dialysis Transplantation, 2010, 25, 2672-2679.	0.7	77
107	Thrombospondin 1 is expressed by proliferating mesangial cells and is up-regulated by PDGF and bFGF in vivo. Kidney International, 1995, 48, 1846-1856.	5.2	76
108	The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 791-799.	4.5	75

#	Article	IF	Citations
109	Pathways to Recovery and Loss of Nephrons in Anti-Thy-1 Nephritis. Journal of the American Society of Nephrology: JASN, 2003, 14, 1904-1926.	6.1	73
110	Dickkopf-3 (DKK3) in Urine Identifies Patients with Short-Term Risk of eGFR Loss. Journal of the American Society of Nephrology: JASN, 2018, 29, 2722-2733.	6.1	73
111	Keratins are novel markers of renal epithelial cell injury. Kidney International, 2016, 89, 792-808.	5.2	72
112	PDGF-C Expression in the Developing and Normal Adult Human Kidney and in Glomerular Diseases. Journal of the American Society of Nephrology: JASN, 2003, 14, 1145-1153.	6.1	69
113	Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol. Nephrology Dialysis Transplantation, 2014, 29, 1633-1638.	0.7	68
114	Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. Nephrology Dialysis Transplantation, 2020, 35, 1002-1009.	0.7	66
115	Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 673-684.	4.5	66
116	Recurrent glomerulonephritis following renal transplantation: an update. Nephrology Dialysis Transplantation, 2003, 18, 1260-1265.	0.7	65
117	Antagonism of PDGF-D by Human Antibody CR002 Prevents Renal Scarring in Experimental Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2006, 17, 1054-1062.	6.1	64
118	Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. Nephrology Dialysis Transplantation, 2013, 28, 146-152.	0.7	64
119	Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2018, 29, 317-325.	6.1	64
120	Association of fetuin-A levels with the progression of aortic valve calcification in non-dialyzed patients. European Heart Journal, 2009, 30, 2054-2061.	2.2	63
121	The Clinical Course of Treated Hyperparathyroidism Among Patients Receiving Hemodialysis and the Effect of Cinacalcet: The EVOLVE Trial. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4834-4844.	3.6	63
122	Expression of a Novel PDGF Isoform, PDGF-C, in Normal and Diseased Rat Kidney. Journal of the American Society of Nephrology: JASN, 2002, 13, 910-917.	6.1	62
123	Electrical Forces Determine Glomerular Permeability. Journal of the American Society of Nephrology: JASN, 2010, 21, 2053-2058.	6.1	61
124	Subtotal Ablation of Parietal Epithelial Cells Induces Crescent Formation. Journal of the American Society of Nephrology: JASN, 2012, 23, 629-640.	6.1	61
125	Role of T cells and dendritic cells in glomerular immunopathology. Seminars in Immunopathology, 2007, 29, 317-335.	6.1	57
126	Common histological patterns in glomerular epithelial cells in secondary focal segmental glomerulosclerosis. Kidney International, 2015, 88, 990-998.	5.2	57

#	Article	IF	Citations
127	Effects of Retinoids on the TGF-Î² System and Extracellular Matrix in Experimental Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2001, 12, 2300-2309.	6.1	57
128	Big science and big data in nephrology. Kidney International, 2019, 95, 1326-1337.	5.2	56
129	Elastin imaging enables noninvasive staging and treatment monitoring of kidney fibrosis. Science Translational Medicine, 2019, 11, .	12.4	56
130	Regulation of Mesangial Cell Proliferation. American Journal of Kidney Diseases, 1991, 17, 673-676.	1.9	55
131	Role of interleukin-6 in mediating mesangial cell proliferation and matrix production in vivo. Kidney International, 1997, 51, 69-78.	5.2	55
132	PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis. Nephrology Dialysis Transplantation, 2007, 22, 1323-1331.	0.7	55
133	Adynamic bone disease--bone and beyond. CKJ: Clinical Kidney Journal, 2008, 1, 135-147.	2.9	55
134	Primary Cultures of Glomerular Parietal Epithelial Cells or Podocytes with Proven Origin. PLoS ONE, 2012, 7, e34907.	2.5	55
135	Monokines and platelet-derived growth factor modulate prostanoid production in growth arrested, human mesangial cells. Kidney International, 1990, 37, 859-869.	5.2	54
136	New insights into the pathogenesis of IgA nephropathy. Seminars in Immunopathology, 2014, 36, 431-442.	6.1	53
137	Serum and urine markers of collagen degradation reflect renal fibrosis in experimental kidney diseases. Nephrology Dialysis Transplantation, 2015, 30, 1112-1121.	0.7	53
138	Phosphate binders in chronic kidney disease: a systematic review of recent data. Journal of Nephrology, 2016, 29, 329-340.	2.0	53
139	Platelet-derived growth factor: A potentially important cytokine in glomerular disease. Kidney International, 1992, 41, 590-594.	5.2	52
140	Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis?. Nephrology Dialysis Transplantation, 2016, 31, 1211-1219.	0.7	52
141	Current treatment of IgA nephropathy. Seminars in Immunopathology, 2021, 43, 717-728.	6.1	52
142	C-type natriuretic peptide inhibits mesangial cell proliferation and matrix accumulation in vivo. Kidney International, 1998, 53, 1143-1151.	5.2	50
143	Clinical Predictors of Individual Cognitive Fluctuations in Patients Undergoing Hemodialysis. American Journal of Kidney Diseases, 2014, 64, 434-442.	1.9	50
144	Novel parietal epithelial cell subpopulations contribute to focal segmental glomerulosclerosis and glomerular tip lesions. Kidney International, 2019, 96, 80-93.	5.2	50

#	Article	IF	Citations
145	Developmental stages of tertiary lymphoid tissue reflect local injury and inflammation in mouse and human kidneys. Kidney International, 2020, 98, 448-463.	5.2	50
146	Altered glomerular extracellular matrix synthesis in experimental membranous nephropathy. Kidney International, 1992, 42, 573-585.	5.2	48
147	Localization of PDGF Î±-receptor in the developing and mature human kidney. Kidney International, 1997, 51, 1140-1150.	5.2	48
148	Vasculoprotective Effects of Dietary Cocoa Flavanols in Patients on Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 108-118.	4.5	46
149	Investigations of Glucocorticoid Action in GN. Journal of the American Society of Nephrology: JASN, 2017, 28, 1408-1420.	6.1	46
150	Key metalloproteinase-mediated pathways in the kidney. Nature Reviews Nephrology, 2021, 17, 513-527.	9.6	46
151	The Effects of Platelet-Derived Growth Factor Antagonism in Experimental Glomerulonephritis Are Independent of the Transforming Growth Factorâ€Î² System. Journal of the American Society of Nephrology: JASN, 2002, 13, 658-667.	6.1	46
152	Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Nephrology Dialysis Transplantation, 2012, 27, 2872-2879.	0.7	45
153	Turnover of type III collagen reflects disease severity and is associated with progression and microinflammation in patients with IgA nephropathy. Nephrology Dialysis Transplantation, 2016, 31, 472-479.	0.7	45
154	IL-6 Trans-Signaling Drives Murine Crescentic GN. Journal of the American Society of Nephrology: JASN, 2016, 27, 132-142.	6.1	45
155	Glomerular cells in vitro versus the glomerulus in vivo. Kidney International, 1994, 45, 360-368.	5.2	44
156	Platelet-derived growth factors (PDGFs) in glomerular and tubulointerstitial fibrosis. Kidney International Supplements, 2014, 4, 65-69.	14.2	44
157	Diffusionâ€weighted MRI does not reflect kidney fibrosis in a rat model of fibrosis. Journal of Magnetic Resonance Imaging, 2015, 42, 990-998.	3.4	44
158	Deep learning-based classification of kidney transplant pathology: a retrospective, multicentre, proof-of-concept study. The Lancet Digital Health, 2022, 4, e18-e26.	12.3	43
159	MicroRNAs in Chronic Kidney Disease: Four Candidates for Clinical Application. International Journal of Molecular Sciences, 2020, 21, 6547.	4.1	42
160	Modulation of experimental mesangial proliferative nephritis by interferon-Î³. Kidney International, 1995, 47, 62-69.	5.2	41
161	Origin of Parietal Podocytes in Atubular Glomeruli Mapped by Lineage Tracing. Journal of the American Society of Nephrology: JASN, 2014, 25, 129-141.	6.1	41
162	Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial. Kidney International, 2018, 93, 1475-1482.	5.2	41

#	Article	IF	Citations
163	Dysregulated mesenchymal PDGFRâ€Î² drives kidney fibrosis. EMBO Molecular Medicine, 2020, 12, e11021.	6.9	41
164	Urinary Exosomes: A Novel Means to Non-Invasively Assess Changes in Renal Gene and Protein Expression. PLoS ONE, 2014, 9, e109631.	2.5	40
165	Selective Cyclooxygenase-2 Inhibition Impairs Glomerular Capillary Healing in Experimental Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2002, 13, 1261-1270.	6.1	40
166	Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients. Nephrology Dialysis Transplantation, 2010, 25, 1916-1923.	0.7	38
167	PDGF-C Mediates Glomerular Capillary Repair. American Journal of Pathology, 2010, 177, 58-69.	3.8	38
168	The role of PDGF-D in healthy and fibrotic kidneys. Kidney International, 2016, 89, 848-861.	5.2	38
169	Inflammation in IgA nephropathy. Pediatric Nephrology, 2017, 32, 2215-2224.	1.7	38
170	When man turns to stone: Extraosseous calcification in uremic patients. Kidney International, 2004, 65, 2447-2462.	5.2	37
171	Why Target the Gut to Treat IgA Nephropathy?. Kidney International Reports, 2020, 5, 1620-1624.	0.8	37
172	Do not be misguided by guidelines: the calcium x phosphate product can be a Trojan horse. Nephrology Dialysis Transplantation, 2005, 20, 673-677.	0.7	36
173	CD153/CD30 signaling promotes age-dependent tertiary lymphoid tissue expansion and kidney injury. Journal of Clinical Investigation, 2022, 132, .	8.2	36
174	Novel 3D analysis using optical tissue clearing documents the evolution of murine rapidly progressive glomerulonephritis. Kidney International, 2019, 96, 505-516.	5.2	35
175	Sodium thiosulphate and progression of vascular calcification in end-stage renal disease patients: a double-blind, randomized, placebo-controlled study. Nephrology Dialysis Transplantation, 2020, 35, 162-169.	0.7	35
176	A collagen-binding protein enables molecular imaging of kidney fibrosis inÂvivo. Kidney International, 2020, 97, 609-614.	5.2	34
177	Calcineurin-mediated YB-1 Dephosphorylation Regulates CCL5 Expression during Monocyte Differentiation. Journal of Biological Chemistry, 2014, 289, 21401-21412.	3.4	33
178	The vulnerable patient with chronic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 382-390.	0.7	33
179	Phosphate binders in chronic kidney disease: an updated narrative review of recent data. Journal of Nephrology, 2020, 33, 497-508.	2.0	33
180	SGLT-2 inhibition in IgA nephropathy: the new standard of care?. Kidney International, 2021, 100, 24-26.	5.2	33

#	Article	IF	Citations
181	Therapeutic nuclear shuttling of YB-1 reduces renal damage and fibrosis. Kidney International, 2016, 90, 1226-1237.	5.2	32
182	Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrology Dialysis Transplantation, 2017, 32, gfw242.	0.7	32
183	Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores). BMC Nephrology, 2018, 19, 328.	1.8	31
184	IgA nephropathy: new insights into the role of complement. Kidney International, 2018, 94, 16-18.	5.2	31
185	A Novel Role for GATA3 in Mesangial Cells in Glomerular Development and Injury. Journal of the American Society of Nephrology: JASN, 2019, 30, 1641-1658.	6.1	31
186	Analysis of Calcifications in Patients with Coral Reef Aorta. Annals of Vascular Surgery, 2010, 24, 408-414.	0.9	30
187	Blood Pressure Pattern and Target Organ Damage in Patients With Chronic Kidney Disease. Hypertension, 2018, 72, 929-936.	2.7	29
188	Augmentation of kidney injury by basic fibroblast growth factor or platelet-derived growth factor does not induce progressive diabetic nephropathy in the Goto Kakizaki model of non-insulin-dependent diabetes. Translational Research, 1999, 134, 304-312.	2.3	28
189	R-roscovitine (CYC202) alleviates renal cell proliferation in nephritis without aggravating podocyte injury. Kidney International, 2005, 67, 1362-1370.	5.2	28
190	?Missing? inhibitors of calcification: general aspects and implications in renal failure. Pediatric Nephrology, 2005, 20, 383-388.	1.7	28
191	Magnesium in CKD: more than a calcification inhibitor?. Journal of Nephrology, 2015, 28, 269-277.	2.0	28
192	Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney diseaseâ€“mineral bone disorder parameters in dialysis patients. Nephrology Dialysis Transplantation, 2019, 34, 1163-1170.	0.7	28
193	Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis. American Journal of Kidney Diseases, 2021, 78, 340-349.e1.	1.9	28
194	Evidence-based recommendations for immunosuppression in IgA nephropathy: handle with caution. Nephrology Dialysis Transplantation, 2003, 18, 241-245.	0.7	27
195	Recurrent IgA nephropathy in the renal allograft: not a benign condition. Nephrology Dialysis Transplantation, 2013, 28, 1070-1073.	0.7	27
196	Osteogenesis of Heterotopically Transplanted Mesenchymal Stromal Cells in Rat Models of Chronic Kidney Disease. Journal of Bone and Mineral Research, 2013, 28, 2523-2534.	2.8	26
197	Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation. Nephrology Dialysis Transplantation, 2018, 33, 1683-1689.	0.7	26
198	Non-invasive molecular imaging of kidney diseases. Nature Reviews Nephrology, 2021, 17, 688-703.	9.6	26

#	Article	IF	Citations
199	A Novel, Dual Role of CCN3 in Experimental Glomerulonephritis. American Journal of Pathology, 2012, 180, 1979-1990.	3.8	25
200	Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University. Clinical Research in Cardiology, 2018, 107, 120-126.	3.3	25
201	Hypoglycemia following intravenous insulin plus glucose for hyperkalemia in patients with impaired renal function. PLoS ONE, 2017, 12, e0172961.	2.5	25
202	Advanced Tertiary Lymphoid Tissues in Protocol Biopsies are Associated with Progressive Graft Dysfunction in Kidney Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2022, 33, 186-200.	6.1	25
203	Effects and mechanisms of angiotensin II receptor blockade with telmisartan in a normotensive model of mesangioproliferative nephritis. Nephrology Dialysis Transplantation, 2011, 26, 3131-3143.	0.7	24
204	The platelet-derived growth factor system in renal disease: An emerging role of endogenous inhibitors. European Journal of Cell Biology, 2012, 91, 542-551.	3.6	24
205	Complement C5a receptors C5L2 and C5aR in renal fibrosis. American Journal of Physiology - Renal Physiology, 2018, 314, F35-F46.	2.7	24
206	Platelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 155-170.	4.5	24
207	Management of hyperphosphataemia in chronic kidney disease--challenges and solutions. CKJ: Clinical Kidney Journal, 2013, 6, 128-136.	2.9	23
208	Nephrology researchâ€"the past, present and future. Nature Reviews Nephrology, 2015, 11, 677-687.	9.6	23
209	FGF-23 levels are associated with vascular calcification, but not with atherosclerosis, in hemodialysis patients. International Urology and Nephrology, 2016, 48, 609-617.	1.4	23
210	<scp>YB</scp>â€1 orchestrates onset and resolution of renal inflammation via <scp>IL</scp>10 gene regulation. Journal of Cellular and Molecular Medicine, 2017, 21, 3494-3505.	3.6	23
211	Serum phosphate optimal timing and range associated with patients survival in haemodialysis: the COSMOS study. Nephrology Dialysis Transplantation, 2019, 34, 673-681.	0.7	23
212	Magnesium but not nicotinamide prevents vascular calcification in experimental uraemia. Nephrology Dialysis Transplantation, 2020, 35, 65-73.	0.7	23
213	Association Between Dietary Patterns and Kidney Function in Patients With Chronic Kidney Disease: A Cross-Sectional Analysis of the German Chronic Kidney Disease Study. , 2020, 30, 296-304.		23
214	Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. Kidney International, 2021, 100, 1199-1207.	5.2	23
215	Increased Cerebral Water Content in Hemodialysis Patients. PLoS ONE, 2015, 10, e0122188.	2.5	22
216	Contrast-enhanced CT imaging in patients with chronic kidney disease. Angiogenesis, 2016, 19, 525-535.	7.2	22

#	Article	IF	Citations
217	One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrology Dialysis Transplantation, 2017, 32, 1918-1926.	0.7	21
218	High-fat diet-induced obesity causes an inflammatory microenvironment in the kidneys of aging Long-Evans rats. Journal of Inflammation, 2019, 16, 14.	3.4	21
219	Altered vitamin K biodistribution and metabolism in experimental and human chronic kidney disease. Kidney International, 2022, 101, 338-348.	5.2	21
220	New Aspects of Kidney Fibrosisâ€“From Mechanisms of Injury to Modulation of Disease. Frontiers in Medicine, 2021, 8, 814497.	2.6	21
221	Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS. Nephrology Dialysis Transplantation, 2022, 37, 1400-1410.	0.7	21
222	Gp130-dependent signaling in the podocyte. American Journal of Physiology - Renal Physiology, 2014, 307, F346-F355.	2.7	20
223	Cold shock protein YB-1 is involved in hypoxia-dependent gene transcription. Biochemical and Biophysical Research Communications, 2016, 478, 982-987.	2.1	20
224	Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 539-546.	4.5	20
225	Sclerostin deficiency modifies the development of CKD-MBD in mice. Bone, 2018, 107, 115-123.	2.9	20
226	Standardized Outcomes in Nephrologyâ€”Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease. Kidney International, 2019, 95, 1280-1283.	5.2	20
227	Disruption of CUL3-mediated ubiquitination causes proximal tubule injury and kidney fibrosis. Scientific Reports, 2019, 9, 4596.	3.3	20
228	Immune Modulating Therapy for IgA Nephropathy: Rationale and Evidence. Seminars in Nephrology, 2008, 28, 38-47.	1.6	19
229	Role of Platelet-Derived Growth Factor-CC in Capillary Rarefaction in Renal Fibrosis. American Journal of Pathology, 2015, 185, 2132-2142.	3.8	19
230	Cinacalcet, dialysate calcium concentration, and cardiovascular events in the <scp>EVOLVE</scp> trial. Hemodialysis International, 2016, 20, 421-431.	0.9	19
231	Association of changes in bone mineral parameters with mortality in haemodialysis patients: insights from the ARO cohort. Nephrology Dialysis Transplantation, 2020, 35, 478-487.	0.7	19
232	Vitamin K and cardiovascular complications in chronic kidney disease patients. Kidney International, 2021, 100, 1023-1036.	5.2	19
233	Platelet Hyperaggregability is Highly Prevalent in Patients With Chronic Kidney Disease. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 132-138.	1.7	18
234	Gas6 protein: its role in cardiovascular calcification. BMC Nephrology, 2016, 17, 52.	1.8	18

#	Article	IF	Citations
235	The YB-1:Notch-3 axis modulates immune cell responses and organ damage in systemic lupus erythematosus. Kidney International, 2020, 97, 289-303.	5.2	18
236	Propensity score matching and persistence correction to reduce bias in comparative effectiveness: the effect of cinacalcet use on allâ€cause mortality. Pharmacoepidemiology and Drug Safety, 2015, 24, 738-747.	1.9	17
237	Trends of renal diseases in Germany: review of a regional renal biopsy database from 1990 to 2013. CKJ: Clinical Kidney Journal, 2019, 12, 795-800.	2.9	17
238	Calcification and the usual suspect phosphate: still guilty but there are other guys behind the scenes. Nephrology Dialysis Transplantation, 2006, 21, 33-35.	0.7	15
239	ACEIs with or without corticosteroids in IgA nephropathy?. Nature Reviews Nephrology, 2010, 6, 252-254.	9.6	15
240	Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial. European Heart Journal, 2021, 42, 1228-1230.	2.2	15
241	The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics. American Journal of Nephrology, 2021, 52, 827-836.	3.1	15
242	Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure. ESC Heart Failure, 2022, 9, 2233-2238.	3.1	15
243	Magnesium Concentration in Dialysate. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1309-1310.	4.5	14
244	Identification of platelet-derived growth factor C as a mediator of both renal fibrosis and hypertension. Kidney International, 2019, 95, 1103-1119.	5.2	14
245	A Functional Landscape of CKD Entities From Public Transcriptomic Data. Kidney International Reports, 2020, 5, 211-224.	0.8	14
246	Evidence of an intestinal phosphate transporter alternative to type IIb sodium-dependent phosphate transporterÂin rats with chronic kidney disease. Nephrology Dialysis Transplantation, 2021, 36, 68-75.	0.7	14
247	Low adherence to CKD-specific dietary recommendations associates with impaired kidney function, dyslipidemia, and inflammation. European Journal of Clinical Nutrition, 2021, 75, 1389-1397.	2.9	14
248	Recommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemic. Nephrology Dialysis Transplantation, 2020, 35, 920-925.	0.7	14
249	Current kidney function parameters overestimate kidney tissue repair in reversible experimental kidney disease. Kidney International, 2022, 102, 307-320.	5.2	14
250	The SDF-1/CXCR4 Axis Is a Novel Driver of Vascular Development of the Glomerulus. Journal of the American Society of Nephrology: JASN, 2009, 20, 1659-1661.	6.1	13
251	Kidney calling lung and call back: how organs talk to each other. Nephrology Dialysis Transplantation, 2010, 25, 32-34.	0.7	13
252	Epicardial adipose tissue in long-term hemodialysis patients: its association with vascular calcification and long-term development. Journal of Nephrology, 2016, 29, 241-250.	2.0	13

#	Article	IF	Citations
253	Non-invasive evaluation of coronary heart disease in patients with chronic kidney disease using photoplethysmography. CKJ: Clinical Kidney Journal, 2019, 12, 538-545.	2.9	13
254	The nucleic acid binding protein YB-1â€“controlled expression of CXCL-1 modulates kidney damage inÂliver fibrosis. Kidney International, 2020, 97, 741-752.	5.2	13
255	Single versus dual blockade of the renin-angiotensin system in patients with IgA nephropathy. Journal of Nephrology, 2020, 33, 1231-1239.	2.0	13
256	Cardiovascular disease in patients with chronic kidney disease. Herz, 2020, 45, 122-128.	1.1	13
257	An efficient system for tissue-specific overexpression of transgenes in podocytes in vivo. American Journal of Physiology - Renal Physiology, 2005, 289, F481-F488.	2.7	12
258	The Role of PDGF-D in Mesangioproliferative Glomerulonephritis. , 2007, 157, 153-158.		12
259	Mesenchymal stem cells as a therapeutic approach to glomerular diseases: benefits and risks. Kidney International Supplements, 2011, 1, 68-73.	14.2	12
260	Primary glomerulonephritis: A review of important recent discoveries. Kidney Research and Clinical Practice, 2013, 32, 103-110.	2.2	12
261	Uremic Toxins Affecting Cardiovascular Calcification: A Systematic Review. Cells, 2020, 9, 2428.	4.1	12
262	Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism. Nefrologia, 2016, 36, 164-175.	0.4	11
263	The new SFB/TRR219 Research Centre. European Heart Journal, 2018, 39, 975-977.	2.2	11
264	Combining phosphate binder therapy with vitamin K2 inhibits vascular calcification in an experimental animal model of kidney failure. Nephrology Dialysis Transplantation, 2022, 37, 652-662.	0.7	11
265	Management of Intraocular Hypertension During Hemodialysis by Intravenous Glucose Administration. American Journal of Kidney Diseases, 2014, 63, 500-502.	1.9	10
266	Cold Shock Proteins Mediate GN with Mesangioproliferation. Journal of the American Society of Nephrology: JASN, 2016, 27, 3678-3689.	6.1	10
267	Mucosal corticosteroid therapy ofÂIgA nephropathy. Kidney International, 2017, 92, 278-280.	5.2	10
268	IgA nephropathy: toward more specific diagnosis (and rescue of snails). Kidney International, 2018, 93, 542-544.	5.2	10
269	Longâ€term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients. Hemodialysis International, 2018, 22, 480-491.	0.9	10
270	YB-1 increases glomerular, but decreases interstitial fibrosis in CNI-induced nephropathy. Clinical Immunology, 2018, 194, 67-74.	3.2	10

#	Article	IF	Citations
271	Management and treatment of glomerular diseases (part 1): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Nephrology (Saint-Petersburg), 2020, 24, 22-41.	0.4	10
272	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. Journal of the American Society of Nephrology: JASN, 2022, 33, 291-303.	6.1	10
273	The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021. Nephrology Dialysis Transplantation, 2023, 38, 551-561.	0.7	10
274	Antagonism of Canonical Wnt/Î²-Catenin Signaling: Taking RAS Blockade to the Next Level?. Journal of the American Society of Nephrology: JASN, 2015, 26, 3-5.	6.1	9
275	Con: STOP immunosuppression in IgA nephropathy. Nephrology Dialysis Transplantation, 2016, 31, 1771-1774.	0.7	9
276	Calcification in arteriovenous fistula blood vessels may predict arteriovenous fistula failure: a 5-year follow-up study. International Urology and Nephrology, 2017, 49, 881-887.	1.4	9
277	Sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opinion on Pharmacotherapy, 2018, 19, 1137-1148.	1.8	9
278	Speckle Tracking Echocardiography and All-Cause and Cardiovascular Mortality Risk in Chronic Kidney Disease Patients. Kidney and Blood Pressure Research, 2019, 44, 690-703.	2.0	9
279	Cardiovascular complications of chronic kidney disease: pioneering studies. Kidney International, 2020, 98, 522-526.	5.2	9
280	Hospitalization and mortality following non-attendance for hemodialysis according to dialysis day of the week: a European cohort study. BMC Nephrology, 2020, 21, 218.	1.8	9
281	Glomerular Remodelling: Novel Therapeutic Approaches Derived from the Apparently Chaotic Growth Factor Network. Nephron, 2002, 91, 582-587.	1.8	8
282	Goto-Kakizaki rat is protected from proteinuria after induction of anti-Thy1 nephritis. American Journal of Kidney Diseases, 2002, 39, 985-1000.	1.9	8
283	Anti-interleukin-6 therapy through application of a monogenic protein inhibitor via gene delivery. Scientific Reports, 2015, 5, 14685.	3.3	8
284	Klotho Deficiency and the Cardiomyopathy of Advanced CKD. Journal of the American Society of Nephrology: JASN, 2015, 26, 1229-1231.	6.1	8
285	Glomerulonephritis triggered by a chronically infected left ventricular assist device. Lancet, The, 2015, 386, 2363-2364.	13.7	8
286	Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism. Nefrologia, 2016, 36, 164-175.	0.4	8
287	Prognostic value of cardiovascular calcifications in hemodialysis patients: a longitudinal study. International Urology and Nephrology, 2018, 50, 939-946.	1.4	8
288	Epicardial fat, cardiovascular risk factors and calcifications in patients with chronic kidney disease. CKJ: Clinical Kidney Journal, 2020, 13, 571-579.	2.9	8

#	Article	IF	Citations
289	Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: predictors, therapeutic approaches and outcomes. Journal of Nephrology, 2020, 33, 803-816.	2.0	8
290	Cardiovascular disease in patients with chronic kidney disease. Herz, 2021, 46, 205-205.	1.1	8
291	Educational Attainment Is Associated With Kidney and Cardiovascular Outcomes in the German CKD (GCKD) Cohort. Kidney International Reports, 2022, 7, 1004-1015.	0.8	8
292	How I Treat IgA Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 1243-1246.	4.5	8
293	Assessing prognosis in IgA nephropathy. Kidney International, 2022, 102, 22-24.	5.2	8
294	Bone marrow transplantation rescues Alport mice*. Nephrology Dialysis Transplantation, 2006, 21, 2721-2723.	0.7	7
295	Inverse correlation between vascular endothelial growth factor back-filtration and capillary filtration pressures. Nephrology Dialysis Transplantation, 2018, 33, 1514-1525.	0.7	7
296	Left Ventricular Structure in Patients With Mild-to-Moderate CKDâ€"a Magnetic Resonance Imaging Study. Kidney International Reports, 2019, 4, 267-274.	0.8	7
297	Hyperuricemia and progression of chronic kidney disease: to treat or not to treat?. Kidney International, 2021, 99, 14-16.	5.2	7
298	Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease. Kidney International, 2021, 100, 881-893.	5.2	7
299	The management of membranous nephropathyâ€"an update. Nephrology Dialysis Transplantation, 2022, 37, 1033-1042.	0.7	7
300	Is mycophenolate mofetil an effective treatment for persistent proteinuria in patients with IgA nephropathy?. Nature Clinical Practice Nephrology, 2006, 2, 16-17.	2.0	6
301	Clinical Outcomes in Secondary Hyperparathyroidism and the Potential Role of Calcimimetics. CKJ: Clinical Kidney Journal, 2008, 1, i29-i35.	2.9	6
302	CTLA-4 Polymorphisms in Patients with IgA Nephropathy Correlate with Proteinuria. Kidney and Blood Pressure Research, 2018, 43, 360-366.	2.0	6
303	Urinary Biomarkers in the Prediction of Prognosis and Treatment Response in IgA Nephropathy. Kidney and Blood Pressure Research, 2018, 43, 1563-1572.	2.0	6
304	Antimalarials in IgA Nephropathy: Did Our Supportive Therapy Armamentarium Just Increase?. American Journal of Kidney Diseases, 2019, 74, 6-8.	1.9	6
305	Monitoring transcellular fluid shifts during episodes of intradialytic hypotension using bioimpedance spectroscopy. CKJ: Clinical Kidney Journal, 2021, 14, 149-155.	2.9	6
306	Challenging the use of warfarin in patients on dialysis with atrial fibrillation. Nature Reviews Nephrology, 2015, 11, 450-450.	9.6	5

#	Article	IF	Citations
307	IgA nephropathy: a perspective for 2021. Seminars in Immunopathology, 2021, 43, 625-626.	6.1	5
308	Survival on four compared with three times per week haemodialysis in high ultrafiltration patients: an observational study. CKJ: Clinical Kidney Journal, 2021, 14, 665-672.	2.9	5
309	How effective and safe are antiplatelet agents in CKD?. Nature Reviews Nephrology, 2013, 9, 314-316.	9.6	4
310	Efficacy of corticosteroids in high-risk IgA nephropathy. Nature Reviews Nephrology, 2015, 11, 319-320.	9.6	4
311	Immunosuppression in IgA nephropathy: how certain are we?. Kidney International, 2016, 89, 9-11.	5.2	4
312	Prognostic assessment of IgA nephropathy: how much does histology add?. Kidney International, 2016, 89, 19-21.	5.2	4
313	Rituximab therapy for IgA nephropathy. Nature Reviews Nephrology, 2017, 13, 138-140.	9.6	4
314	Cre recombinase toxicity in podocytes: a novel genetic model for FSGS in adolescent mice. American Journal of Physiology - Renal Physiology, 2019, 317, F1375-F1382.	2.7	4
315	Mineral and bone disorder in chronic kidney disease: pioneering studies. Kidney International, 2020, 98, 807-811.	5.2	4
316	Precision medicine in immunoglobulin AÂnephropathy: still a journey ahead. Nephrology Dialysis Transplantation, 2021, 36, 24-30.	0.7	4
317	Rationale and design of XARENO: XA inhibition in RENal patients with non-valvular atrial fibrillation. Observational registry. Kardiologia Polska, 2021, 79, 1265-1267.	0.6	4
318	A Core Outcome Set for Trials in Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 53-64.	4.5	4
319	Mutant mice provide new insight into the role of (mis-)glycation in IgA nephropathy and other glomerular diseases. Nephrology Dialysis Transplantation, 2007, 22, 1518-1520.	0.7	3
320	The longer the better: follow-up in seemingly â€˜benignâ€™ immunoglobulin A nephropathy. Nephrology Dialysis Transplantation, 2017, 32, 1777-1779.	0.7	3
321	A new tool to predict the risk of progression in IgA nephropathy. Kidney International, 2019, 96, 808-809.	5.2	3
322	Evaluation of Electrocardiographic Parameters Predicting Cardiovascular Events in Patients with End-Stage Renal Disease before and after Transplantation. Kidney and Blood Pressure Research, 2019, 44, 615-627.	2.0	3
323	Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation. Nephrology Dialysis Transplantation, 2020, 35, 946-954.	0.7	3
324	Effects of Perfusion Pressures on Podocyte Loss in the Isolated Perfused Mouse Kidney.. Cellular Physiology and Biochemistry, 2021, 55, 1-12.	1.6	3

#	Article	IF	Citations
325	Immunosuppressant-induced reduction of proteinuria in IgAN. Nature Reviews Nephrology, 2016, 12, 380-382.	9.6	2
326	Fatal Attraction: Immunoglobulin A and the Glomerular Mesangium. Journal of the American Society of Nephrology: JASN, 2019, 30, 1139-1141.	6.1	2
327	Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study. Nephron, 2020, 144, 428-439.	1.8	2
328	Knee-to-knee bioimpedance measurements to monitor changes in extracellular fluid in haemodynamic-unstable patients during dialysis. Journal of Electrical Bioimpedance, 2019, 10, 55-62.	0.9	2
329	A focus group study of self-management in patients with glomerular disease.. Kidney International Reports, 2021, 7, 56-67.	0.8	2
330	Influence of rivaroxaban compared to vitamin K antagonist treatment upon development of cardiovascular calcification in patients with atrial fibrillation and/or pulmonary embolism. Clinical Cardiology, 2022, 45, 352-358.	1.8	2
331	Potential Risks of Stem Cell Therapies. , 2011, , 361-387.		1
332	Moderator's view: Will 'modern' urine proteomics replace 'old-fashioned' renal biopsy?. Nephrology Dialysis Transplantation, 2015, 30, 538-540.	0.7	1
333	MO025NON-INVASIVE MOLECULAR IMAGING OF KIDNEY FIBROSIS. Nephrology Dialysis Transplantation, 2016, 31, i38-i38.	0.7	1
334	TO032CONSEQUENCES AND FATE OF INTRARENAL CRYSTALS IN ADENINE NEPHROPATHY. Nephrology Dialysis Transplantation, 2016, 31, i74-i74.	0.7	1
335	ISN Nexus 2016 Symposia: Translational Immunology in Kidney Diseaseâ€"The Berlin Roadmap. Kidney International Reports, 2016, 1, 327-339.	0.8	1
336	The STARMEN trial: rethinking calcineurin inhibitor therapy in membranous nephropathy. Kidney International, 2021, 99, 811-813.	5.2	1
337	Parathyroid hormone oxidation in chronic kidney disease: clinical relevance?. Kidney International, 2021, 99, 1070-1072.	5.2	1
338	Authorsâ€™ Reply: Advanced Tertiary Lymphoid Tissues in Protocol Biopsies in Kidney Transplant Recipients: Addressing Additional Methods To Detect Intragraft B Cells. Journal of the American Society of Nephrology: JASN, 2022, , ASN.2021121588.	6.1	1
339	International Physicians Delphi Survey: Managing Patients With IgA Nephropathy. Kidney International Reports, 2022, 7, 2076-2080.	0.8	1
340	Analyse des calcifications chez les patients ayant une atteinte coralliforme de lâ€™aorte. Annales De Chirurgie Vasculaire, 2010, 24, 446-453.	0.0	0
341	SP329VITAMIN K ELIMINATES UREMIC POSTTRANSLATIONAL MODIFICATIONS OF THE GAMMA-GLUTAMYL CARBOXYLASE. Nephrology Dialysis Transplantation, 2016, 31, i200-i200.	0.7	0
342	Opponent's comments. Nephrology Dialysis Transplantation, 2016, 31, 1770-1770.	0.7	0

#	Article	IF	Citations
343	Highlights of the 2015 ERA-EDTA Congressâ€"glomerular diseases. Nephrology Dialysis Transplantation, 2016, 31, gfv433.	0.7	0
344	FP634HIGH ALL CAUSE AND CVD MORTALITY IN AN INCIDENT COHORT OF HEMODIALYSIS PATIENTS WITH LOW SERUM ALBUMIN AND INFLAMMATION. Nephrology Dialysis Transplantation, 2018, 33, i257-i257.	0.7	0
345	FP088HETEROGENEITY AND CLINICAL RELEVANCE OF TERTIARY LYMPHOID TISSUES IN MURINE AND HUMAN KIDNEYS. Nephrology Dialysis Transplantation, 2018, 33, i77-i77.	0.7	0
346	SP406MAGNESIUM AND NICOTINAMIDE: COMPLEMENTARY STRATEGIES AGAINST CALCIFICATION IN EXPERIMENTAL UREMIA. Nephrology Dialysis Transplantation, 2018, 33, i484-i484.	0.7	0
347	The authors reply. Kidney International, 2019, 96, 1422-1423.	5.2	0
348	P0794A REAL-WORLD OBSERVATIONAL STUDY OF ETELCALCETIDE USE IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM IN EUROPE. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
349	P1394ASSOCIATION BETWEEN PARATHYROID HORMONE AND MORTALITY IN HAEMODIALYSIS: THE DIABETES MAKES THE DIFFERENCE. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
350	MO326CORTICOSTEROIDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF REPORTED ADVERSE EVENTS IN RANDOMISED CONTROLLED TRIALS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
351	MO442ACUTE ADVERSE EFFECTS OF LOW POTASSIUM ON HEART AND KIDNEY*. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
352	FC 079HIGH SERUM PHOSPHATE, A NOVEL POTENTIAL RISK FACTOR FOR BONE FRAGILITY FRACTURES IN THE COSMOS STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
353	MO331LINEAGE TRACING OF REGENERATING PROXIMAL TUBULE CELLS (STC) BY SINGLE CELL PROFILING IN ACUTE KIDNEY INJURY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
354	Cytokines and Growth Factors. , 2009, , 243-265.		0
355	Chronische Niereninsuffizienz: StÃ¶rungen im Mineral- und Knochenstoffwechsel. , 2014, , 1-6.		0
356	Heterogeneity and clinical relevance of tertiary lymphoid tissues in murine and human kidney. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-3-24.	0.0	0
357	Survival with low- and high-flux dialysis. CKJ: Clinical Kidney Journal, 2021, 14, 1915-1923.	2.9	0
358	Heart-Type Fatty Acid Binding Protein, Cardiovascular Outcomes, and Death: Findings From the German CKD Cohort Study. American Journal of Kidney Diseases, 2022, , .	1.9	0
359	A Hypercaloric Diet Induces Early Podocyte Damage in Aged, Non-Diabetic Rats. Cellular Physiology and Biochemistry, 2021, 55, 96-112.	1.6	0
360	MO066: The Role of Platelet-Derived Growth Factor in Focal Segmental Glomerulosclerosis. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0

#	Article	IF	Citations
361	MO056: Alteration of Glycocalyx on Endothelium of Peritubular Capillaries in CKD. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0